EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

sCD126 as An Independent Prognostic Biomarker in Critical COVID-19

Giorgos Marinakis, Eleni Karakike, Panagiotis Koufargyris, Maria Patrani, Evangelos J Giamarellos-Bourboulis

Journal of Innate Immunity · 27.04.2026 · 18 (1) · 260-264

DOI: 10.1159/000552271 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Innate Immunity, online erschienen am 27.04.2026. Verfasst von Giorgos Marinakis und 4 weiteren Autor:innen. Beteiligte Einrichtung: Intensive Care Unit, Athens General Hospital "Korgialenio-Benakio", Athens, Greece. Hauptthemen laut MEDLINE: COVID-19, Antibodies, Monoclonal, Humanized, Interleukin-6, Ki-1 Antigen. Die Arbeit nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Biomarkers to predict response of critical COVID-19 to tocilizumab (TCZ) are under investigation. Serum levels of interleukin (IL)-6 and IL-6 soluble receptors were studied in a cohort of patients all receiving treatment with TCZ.

Methods

In this prospective clinical study, IL-6, soluble (s) CD126 and sgp130 were measured in the serum of 127 patients with critical COVID-19 the first 24 h from start of mechanical ventilation and before start of TCZ treatment. Outcome was expressed as the World Health Organization Clinical Progression Scale (WHO-CPS) by day 28. The primary endpoint was the identification of a cut-off of the biomarkers which can predict WHO-CPS 6 or more by day 28.

Results

Stepwise regression analysis with WHO-CPS ≥6 as the outcome and comorbidities, baseline oxygenation and baseline markers of severity showed that sCD126 ≥ 100 ng/mL is independently associated with worse outcome (odds ratio 2.42; 95% confidence intervals 1.05 to 5.63; p: 0.039).

Conclusion

In a cohort of patients with critical COVID-19 receiving TCZ, sCD126 was a predictor of 28-day outcome.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Antibodies, Monoclonal, HumanizedInterleukin-6Ki-1 AntigenHumansFemaleBiomarkersMalePrognosisSARS-CoV-2Prospective StudiesMiddle AgedAgedPandemicsReceptors, Interleukin-6

Stichwörter der Autor:innen

COVID-19Severe pneumoniaTocilizumabsCD126

Substanzen

BiomarkerstocilizumabAntibodies, Monoclonal, HumanizedInterleukin-6Ki-1 AntigenReceptors, Interleukin-6IL6 protein, human

Autor:innen und Institutionen

  • Intensive Care Unit, Athens General Hospital "Korgialenio-Benakio", Athens, Greece.
  • Clinic of Intensive Care and Pulmonary Diseases, Faculty of Nursing, School of Health Sciences, National and Kapodistrian University of Athens, Athens, Greece.
  • 4th Department of Internal Medicine, National and Kapodistrian University of Athens, Medical School, Athens, Greece.
  • 4th Department of Internal Medicine, National and Kapodistrian University of Athens, Medical School, Athens, Greece, egiamarel@med.uoa.gr.

Zitieren

APA

Marinakis, G., Karakike, E., Koufargyris, P., Patrani, M., & Giamarellos-Bourboulis, E. J. (2026). sCD126 as An Independent Prognostic Biomarker in Critical COVID-19. Journal of Innate Immunity, 18(1), 260-264. https://doi.org/10.1159/000552271

Vancouver

Marinakis G, Karakike E, Koufargyris P, Patrani M, Giamarellos-Bourboulis EJ. sCD126 as An Independent Prognostic Biomarker in Critical COVID-19. Journal of Innate Immunity. 2026;18(1):260-264. doi:10.1159/000552271

BibTeX
@article{Marinakis2026,
  author = {Marinakis, Giorgos and Karakike, Eleni and Koufargyris, Panagiotis and Patrani, Maria and Giamarellos-Bourboulis, Evangelos J},
  title = {sCD126 as An Independent Prognostic Biomarker in Critical COVID-19},
  journal = {Journal of Innate Immunity},
  year = {2026},
  volume = {18},
  number = {1},
  pages = {260--264},
  doi = {10.1159/000552271}
}
Kostenlos starten →